Latest Breaking News On - Orphan medicinal products - Page 2 : comparemela.com

CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesYing huangMary ann ondishHemophagocytic lymphohistiocytosisJessie yeungMedicinal devices agencyDrug administrationJanssen biotech incJapan ministry of healthExchange commission onJanssen cilag internationalEuropean commissionEuropean medicines agencyLegend biotech corporationAmerican cancer society

Benitec Biopharma (BNTC) Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301

Benitec Biopharma (BNTC) Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New south walesUnited statesExchange commissionEuropean medicines agencyIrina kofflerlifesci advisorsBenitec or companyBenitec biopharma incDrug administrationCommittee for orphan medicinal productsBenitec biopharmaOculopharyngeal muscular dystrophyOrphan drugOrphan medicinal productsExecutive chairmanChief executive officerNatural history

Shaping the future of Europe s healthcare in a new political cycle

Shaping the future of Europe s healthcare in a new political cycle
euractiv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from euractiv.com Daily Mail and Mail on Sunday newspapers.

Bruxelles capitalePernille weissStefan woxstrMagda chlebusAstra zenecaRichard priceCristian silviu busoiAstra zeneca stefan woxstrEuropean cancer organisationRegulatory affairsEuropean unionEuropean commissionEuropean councilWhile the parliamentWorld health organisationEuropean health data space

Legend Biotech s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

Legend Biotech s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesYing huangMary ann ondishHemophagocytic lymphohistiocytosisBirk vanderweeJessie yeungSurbhi sidanaExchange commission onAmerican cancer societyEuropean commissionJapan ministry of healthLegend biotech corporationOncologic drugs advisory committeeJanssen biotech incMedicinal devices agency

Legend Biotech s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma -April 05, 2024 at 11:31 pm EDT

New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse .

United statesNew jerseyHemophagocytic lymphohistiocytosisSurbhi sidanaBirk vanderweeYing huangMedicinal devices agencyEuropean commissionOncologic drugs advisory committeeLegend biotech corporationDrug administrationJapan ministry of healthJanssen biotech incExchange commission onAmerican cancer societyLegend biotech